Large volume today, hopefully the momentum continues tomorrow. BIIB announced that it has dosed the first patient in the phase III study — TOPAZ-1. This news is from last week on Friday.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
